VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Tuesday, highlighting continued advancement of its proprietary BiTAC(R) platform during the first half of 2026 and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. The company's strategy reflects a focused approach to leveraging its proprietary technology in the competitive field of cancer immunotherapy.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
The BiTAC platform, which stands for bispecific T-cell activating construct, is designed to engage T cells to target and eliminate cancer cells. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company's pipeline reflects a commitment to developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.
Investors and industry observers are closely watching VERAXA's progress as the company moves toward clinical development. The company's ability to secure partnerships and advance its BiTAC candidates will be critical in determining its future success. For more information, the full press release is available on the company's newsroom at http://ibn.fm/VRXA.
VERAXA Biotech AG is listed on NASDAQ under the ticker VRXA. The company is building a premier engine for the discovery and development of antibody-based therapeutics, guided by rigorous quality-by-design principles. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
